KR20240164796A - 새로운 NMO 치료제로서 MHC Ib-매개의 아쿠아포린 4(AQP4)-특이적인 면역억제 - Google Patents

새로운 NMO 치료제로서 MHC Ib-매개의 아쿠아포린 4(AQP4)-특이적인 면역억제 Download PDF

Info

Publication number
KR20240164796A
KR20240164796A KR1020247034451A KR20247034451A KR20240164796A KR 20240164796 A KR20240164796 A KR 20240164796A KR 1020247034451 A KR1020247034451 A KR 1020247034451A KR 20247034451 A KR20247034451 A KR 20247034451A KR 20240164796 A KR20240164796 A KR 20240164796A
Authority
KR
South Korea
Prior art keywords
recombinant polypeptide
amino acid
human
domain
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247034451A
Other languages
English (en)
Korean (ko)
Inventor
발렌틴 브루텔
요에르그 위츠휘센
슈리야 마마타 자야람
파딜 아산
Original Assignee
율리우스-막시밀리안스 우니버지태트 뷔르츠부르크
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 율리우스-막시밀리안스 우니버지태트 뷔르츠부르크 filed Critical 율리우스-막시밀리안스 우니버지태트 뷔르츠부르크
Publication of KR20240164796A publication Critical patent/KR20240164796A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/605—MHC molecules or ligands thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020247034451A 2022-03-24 2023-03-24 새로운 NMO 치료제로서 MHC Ib-매개의 아쿠아포린 4(AQP4)-특이적인 면역억제 Pending KR20240164796A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22164161.6A EP4249062A1 (en) 2022-03-24 2022-03-24 Mhc ib-mediated aquaporin 4 (aqp4)-specific immunosuppression as a novel treatment for nmo
EP22164161.6 2022-03-24
PCT/EP2023/057684 WO2023180549A1 (en) 2022-03-24 2023-03-24 Mhc ib-mediated aquaporin 4 (aqp4)-specific immunosuppression as a novel treatment for nmo

Publications (1)

Publication Number Publication Date
KR20240164796A true KR20240164796A (ko) 2024-11-20

Family

ID=81325683

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247034451A Pending KR20240164796A (ko) 2022-03-24 2023-03-24 새로운 NMO 치료제로서 MHC Ib-매개의 아쿠아포린 4(AQP4)-특이적인 면역억제

Country Status (12)

Country Link
US (1) US20250205322A1 (https=)
EP (2) EP4249062A1 (https=)
JP (1) JP2025510786A (https=)
KR (1) KR20240164796A (https=)
CN (1) CN119110810A (https=)
AU (1) AU2023237632A1 (https=)
CA (1) CA3250911A1 (https=)
CL (1) CL2024002725A1 (https=)
CO (1) CO2024012332A2 (https=)
IL (1) IL314754A (https=)
MX (1) MX2024011666A (https=)
WO (1) WO2023180549A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025061917A1 (en) * 2023-09-22 2025-03-27 Julius-Maximilians-Universität Würzburg Mhc ib-mediated aquaporin 4 (aqp4)-specific immunosuppression as a novel treatment for nmo

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9234017B2 (en) * 2012-12-11 2016-01-12 The Regents Of The University Of California Aquaporin-4 peptide compositions and methods of use thereof
WO2018185564A2 (en) * 2017-04-07 2018-10-11 Uti Limited Partnership Assay to measure the potency of receptor-ligand interactions in nanomedicines
EP3630809A1 (en) 2017-05-23 2020-04-08 Bruttel, Valentin Combinations of mhc class ib molecules and peptides for targeted therapeutic immunomodulation
US20230114434A1 (en) * 2020-03-13 2023-04-13 Codiak Biosciences, Inc. Extracellular vesicles for treating neurological disorders

Also Published As

Publication number Publication date
WO2023180549A1 (en) 2023-09-28
CA3250911A1 (en) 2023-09-28
EP4499231A1 (en) 2025-02-05
EP4249062A1 (en) 2023-09-27
AU2023237632A1 (en) 2024-08-15
CO2024012332A2 (es) 2024-09-30
MX2024011666A (es) 2024-09-27
CN119110810A (zh) 2024-12-10
JP2025510786A (ja) 2025-04-15
US20250205322A1 (en) 2025-06-26
IL314754A (en) 2024-10-01
CL2024002725A1 (es) 2025-02-14

Similar Documents

Publication Publication Date Title
CN113454110A (zh) Ny-eso-1 t细胞受体和其使用方法
KR20210054543A (ko) 조작된 조절 t 세포
US20110097334A1 (en) Novel Marker Genes for Regulatory T Cells from Human Blood
KR20240164796A (ko) 새로운 NMO 치료제로서 MHC Ib-매개의 아쿠아포린 4(AQP4)-특이적인 면역억제
US20180265557A1 (en) Complement split product C4d for the treatment of inflammatory conditions
JP2026065089A (ja) Ｄｃａｆ４ｌ２特異的ｔ細胞受容体
KR20240162578A (ko) 다발성 경화증 및 MOG 항체 질환의 새로운 치료제로서 MHC Ib-매개 미엘린-특이적인 면역억제
KR102169902B1 (ko) 펩타이드
AU2024346292A1 (en) Mhc ib-mediated aquaporin 4 (aqp4)-specific immunosuppression as a novel treatment for nmo
KR20240167684A (ko) 새로운 1형 당뇨병 치료제로서 MHC Ib-매개의 섬-항원-특이적인 면역억제
TW202519540A (zh) MHC Ib媒介之髓磷脂特異性免疫抑制作為用於多發性硬化症及MOG抗體疾病之新穎治療
CA3146205A1 (en) Method
EA048220B1 (ru) Т-клеточные рецепторы к предпочтительно экспрессируемому антигену меланомы (prame) и способы их применения
Frenati Role of CYBR, a cytohesin binder and regulator scaffold protein, in cell-mediated immune response in vivo

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20241016

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application